{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:13:02Z","timestamp":1791252782100,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"Supplement_I","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The therapy of transthyretin (TTR)-related cardiac amyloidosis consists, on the one hand, of the prevention and management of complications (supportive therapy) and on the other of treatments aimed at interrupting or slowing down the production and deposition of fibrils (disease-modifying therapy). This definition includes drugs that act on different phases of amyloidogenesis: (i) silencing of the gene encoding TTR (small interfering RNA: patisiran, vutrisiran; antisense oligonucleotides: inotersen, eplontersen; new CRISPR Cas-9 drug technology for editing in vivo DNA); (ii) stabilization of circulating TTR to inhibit its dissociation and subsequent assembly of the resulting monomers in amyloidotic fibrils (tafamidis, acoramidis, and tolcapone); (iii) destruction and re-absorption of already formed amyloid tissue deposits. Drugs related to the latter strategy (antibodies) are still the subject of Phase 1 or 2 studies.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suac104","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T15:19:29Z","timestamp":1668266369000},"page":"I131-I138","source":"Crossref","is-referenced-by-count":20,"title":["The treatment of amyloidosis is being refined"],"prefix":"10.1093","volume":"24","author":[{"given":"Anna","family":"Cantone","sequence":"first","affiliation":[{"name":"Cardiovascular Centre, University of Ferrara , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Sanguettoli","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, University of Ferrara , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Dal Passo","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, University of Ferrara , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Serenelli","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, University of Ferrara , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[{"name":"Cardiovascular Centre, University of Ferrara , Italy"},{"name":"Maria Cecilia Hospital, GVM Care & Research , Cotignola, Ravenna , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"key":"2022111417533663600_suac104-B1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2022111417533663600_suac104-B2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022111417533663600_suac104-B3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J Intern Med"},{"key":"2022111417533663600_suac104-B4","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"2022111417533663600_suac104-B5","doi-asserted-by":"publisher","DOI":"10.1038\/S41569-022-00683-Z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","author":"Aimo","journal-title":"Nat Rev Cardiol"},{"key":"2022111417533663600_suac104-B6","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1126\/science.1062245","article-title":"Trans-suppression of misfolding in an amyloid disease","volume":"293","author":"Hammarstr\u00f6m","year":"2001","journal-title":"Science"},{"key":"2022111417533663600_suac104-B7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"2022111417533663600_suac104-B8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2022111417533663600_suac104-B9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2020.09.011","article-title":"Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy: further analyses from ATTR-ACT","volume":"9","author":"Rapezzi","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2022111417533663600_suac104-B10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the tafamidis in transthyretin cardiomyopathy clinical trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022111417533663600_suac104-B11","doi-asserted-by":"crossref","first-page":"E008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2022111417533663600_suac104-B12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022111417533663600_suac104-B13"},{"key":"2022111417533663600_suac104-B14","first-page":"1","article-title":"Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity","volume":"71","author":"Sant\u2019Anna","year":"2016","journal-title":"Nat Commun"},{"key":"2022111417533663600_suac104-B15","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/febs.15339","article-title":"Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis","volume":"288","author":"Pinheiro","year":"2021","journal-title":"FEBS J"},{"key":"2022111417533663600_suac104-B16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/13506129.2011.574354073","article-title":"The diflunisal trial: update on study drug tolerance and disease progression","volume":"18","author":"Berk","year":"2011","journal-title":"Amyloid"},{"key":"2022111417533663600_suac104-B17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1751-7133.2012.00303.x","article-title":"Diflunisal for ATTR cardiac amyloidosis","volume":"18","author":"Casta\u00f1o","year":"2012","journal-title":"Congest Heart Fail"},{"key":"2022111417533663600_suac104-B18","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1248\/bpb.b18-00625","article-title":"Recent advances in oligonucleotide-based therapy for transthyretin amyloidosis: clinical impact and future prospects","volume":"41","author":"Hayashi","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"2022111417533663600_suac104-B19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2022111417533663600_suac104-B20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2022111417533663600_suac104-B21","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"2022111417533663600_suac104-B22"},{"key":"2022111417533663600_suac104-B23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022111417533663600_suac104-B24","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.98.18_supplement.2974","article-title":"HELIOS-A: results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy (S8.003)","volume":"98","author":"Adams","year":"2022","journal-title":"Neurology"},{"key":"2022111417533663600_suac104-B25"},{"key":"2022111417533663600_suac104-B26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2022111417533663600_suac104-B27"},{"key":"2022111417533663600_suac104-B28","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"key":"2022111417533663600_suac104-B29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/13506129.2016.1269739","article-title":"Effect of doxycycline and ursodeoxycholic acid on transthyretin amyloidosis","volume":"24","author":"Wixner","year":"2017","journal-title":"Amyloid"},{"key":"2022111417533663600_suac104-B30","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"2022111417533663600_suac104-B31","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11\u20131F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"2022111417533663600_suac104-B32"},{"key":"2022111417533663600_suac104-B33"},{"key":"2022111417533663600_suac104-B34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","article-title":"A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model","volume":"41","author":"George","year":"2020","journal-title":"Eur Heart J"},{"key":"2022111417533663600_suac104-B35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"2022111417533663600_suac104-B36","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"key":"2022111417533663600_suac104-B37","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"key":"2022111417533663600_suac104-B38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_I\/I131\/47030533\/suac104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/24\/Supplement_I\/I131\/47030533\/suac104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T01:50:22Z","timestamp":1728352222000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/24\/Supplement_I\/I131\/6823844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":38,"journal-issue":{"issue":"Supplement_I","published-online":{"date-parts":[[2022,11,12]]},"published-print":{"date-parts":[[2022,11,12]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac104","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,12]]},"published":{"date-parts":[[2022,11,12]]}}}